{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-391358","form_type":"8-K","ticker":"LBRX","cik":"0001691082","company_name":"LB PHARMACEUTICALS INC","filed_at":"2026-09-15T12:05:07+00:00","discovered_at":"2026-09-15T12:10:14.696707+00:00","generated_at":"2026-09-15T12:10:34.152169+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"LB Pharmaceuticals appoints Susan Kozauer as Chief Medical Officer; $515k base, NOVA-2 readout H1 2027","bullets":["Appointed Susan G. Kozauer, M.D. as CMO effective Sept 14, 2026; previously SVP at Centessa and VP at Intra-Cellular.","Compensation: $515k annual base salary, 40% target bonus, $150k sign-on bonus, and 200,000-share option vesting over 4 years.","CEO Heather Turner cites Kozauer's expertise as pivotal for Phase 3 NOVA-2 topline results in schizophrenia expected H1 2027.","Kozauer led clinical development of CAPLYTA across schizophrenia, bipolar disorder, and MDD, resulting in multiple FDA approvals."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-391358","json":"https://secwatch.observer/filing/0001193125-26-391358.json","markdown":"https://secwatch.observer/filing/0001193125-26-391358.md","text":"https://secwatch.observer/filing/0001193125-26-391358.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526391358/0001193125-26-391358-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526391358/d157620d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-15T12:10:34.152169+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9d84d0e652","claim":"Susan G. Kozauer was appointed as Chief Medical Officer at LB PHARMACEUTICALS INC.","evidence_excerpt":"On September 15, 2026, LB Pharmaceuticals Inc (the “Company”) announced that Susan G. Kozauer, M.D. has been appointed to serve as the Company’s Chief Medical Officer, effective as of September 14, 2026 (the “Start Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526391358/0001193125-26-391358-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}